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Summary Over-expression of erbB-2 is associated with shortened survival of patients with lung adenocarcinomas. We demonstrated that
human lung epithelial cells, overexpressing erbB-2, formed tumours in nude mice only when high levels of transforming growth factor (TGF)-a
were produced (E6T cells). To define the role that TGF-a production played in induction of tumorigenicity, a non-tumorigenic TGF-a-negative
clone of ErbB-2 overexpressing cells (E2 cells) was transfected with an expression vectorforTGF-a (E2acells). Transfected clones produced
TGF-a at 11-25% of the level produced by the E6T cell line. Tumorigenic E6T cells transfected with a TGF-a antisense vector (E6TA cells)
expressed only 6% of the TGF-a level of the parental cells. Clones of E6T, E6TA, E2 and E2a were inoculated into athymic nude mice to
measure tumorigenic potential. E6T cells formed tumours with a 70% efficiency. E2, E6TA and E2a cells failed to form tumours. The levels of
EGFR were similar in non-tumorigenic E2 and tumorigenic E6T cells but higher in E2a and E6TA cells, and ErbB-2 were greatly
overexpressed in an E2a clone. In vitro, ErbB-2 co-immunoprecipitated with EGFR in lysates of unstimulated E6T and E2a TGF-a-producing
cells, indicating that the lower TGF-a levels were sufficient to induce in vitro heterodimerization. These studies suggest that induction of the
tumorigenic phenotype depends on achieving a threshold level of TGF-a sufficient to activate downstream signalling by ErbB-2 containing
active heterodimers.
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Lung cancer is currently the leading cause of cancer deaths in
many Western countries (Johnson, 1995). As most lung cancers
arise in the epithelium ofthe bronchial tree, the study ofbronchial
epithelial cells and processes leading to theirmalignant conversion
is ofconsiderable interest. The role that erbB-2 plays in the trans-
formation of bronchial epithelial cells is currently being assessed.
Thirty per cent ofnon-small-cell lung cancers overexpress erbB-2
(Kern et al, 1990; Shi et al, 1994). Overexpression of normal
erbB-2 has been linked to shortened survival in lung adenocarci-
noma (Kern et al, 1992; 1994), suggesting that the expression of
this proto-oncogene may contribute to tumour progression. High
levels of ErbB-2 are also associated with intrinsic multiple drug
resistance (Hancock et al, 1991) and increased metastatic potential
(Yu et al, 1994). However, the mechanism by which overexpres-
sion ofErbB-2 may induce a transformed phenotype is not known.
Although in animal models erbB-2 was shown to cause tumori-
genic conversion because of a single point mutation in the
membrane-spanning region, such mutations are not observed in
human tumours (DiFiore et al, 1987). Human epithelial cells have
stringent requirements for cellular transformation; for example,
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Pierce et al (1991) demonstrated that introduction of a normal
erbB-2 gene into immortalized human mammary epithelial cells
by transfection conferred a growth advantage in vitro. However,
these cells only sporadically produced tumours in nude mice. The
additional genetic changes needed to elicit a fully tumorigenic
phenotype in the presence oferbB-2 are not known.
The expression of other epidermal growth factor receptor
(EGFR) family members and their ligands has been postulated to
contribute to erbB-2-induced tumorigenicity. EGFR family
members have been shown to form heterodimers, the paradigm
being the heterodimerization of EGFR and ErbB-2 induced by
EGFR ligands (King et al, 1988; Kokai et al, 1988).
Overexpression ofboth EGFR and ErbB-2 is necessary to induce a
tumorigenic phenotype in NR6 mouse fibroblasts (Kokai et al,
1989). EGFR ligands do not bind ErbB-2 directly, but cause
EGFR-induced tyrosine phosphorylation of ErbB-2. The func-
tional consequence ofthis interaction after EGF treatment appears
to be the concomitant activation of the in vitro kinase activity of
ErbB-2. In addition, kinase-deficient ErbB-2 proteins display a
dominant negative mutant phenotype, inhibiting both normal
EGFR function and cell transformation induced by the over-
expressed EGFR (Qian et al, 1994). Studies using transgenic mice
suggest that interactions ofErbB-2 and transforming growth factor
(TGF)-a may also play a role in induction of tumorigenicity.
Transgenic strains expressing an EGFR-specific ligand, TGF-at
and wild-type ErbB-2 develop mammary tumours at an accele-
rated rate (Muller et al, 1996).
To examine malignantprogression ofhuman lung epithelial cells
in a model system, erbB-2 was transfected into the immortalized
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human lung epithelial BEAS-2B cell line (Noguchi et al, 1993).
Clonal cell lines were screened for tumorigenicity. Only one of
five tested clones was tumorigenic. This clone, B2BE6 (E6),
expressed the EGFR ligand TGF-ax as well as ErbB-2. Clones
expressing equivalent levels ofErbB-2 and EGFR, but not TGF-X,
failed to produce tumours. We, therefore, postulated that high
TGF-ax production induced heterodimerization of EGFR and
ErbB-2, and that signalling pathways activated by this heterodimer
contributed significantly to the development of the malignant
phenotype.
To test this hypothesis, we manipulated TGF-a production of
ErbB-2-overexpressing cells. Non-tumorigenic E2 cells were trans-
fected with a sense expression vector for TGF-ax, whereas tumori-
genic E6 cells (E6T) were transfected with the same construct in
the antisense orientation. E6T cells expressing TGF-ax antisense
showed a 94% reduction in TGF-ax production and were no
longer tumorigenic. However, E2 cells transfected with TGF-a
in the sense orientation, produced only 9-26% as much
TGF-ax as E6T cells and were not tumorigenic. These results
indicate that production of TGF-a contributes to the tumorigenic
potential ofthese immortalized human bronchial epithelial cells. In
addition, they suggest that expression ofthe characteristics required
for malignant conversion may require high levels ofTGF-ca.
MATERIALS AND METHODS
Cell culture
The BEAS-2B cell line is a non-tumorigenic immortalized human
bronchial epithelial cell line derived from the infection of normal
human bronchial epithelial cells with SV40 adeno 12 hybrid virus.
This cell line retains sensitivity to TGF-P induced squamous
differentiation as well as other characteristics of human bronchial
epithelial cells (Ke et al, 1988). It was grown in LHC-8 medium
(Biofluids, Rockville, MD, USA) according to established proto-
cols (Reddel et al, 1988).
The B2BE2 (E2) and B2BE6 derivatives were prepared by
introducing a wild-type human c-erbB-2 expression vector into
BEAS-2B cells, as previously described (Noguchi et al, 1993).
The B2BE6TM17 cell line (here referred to as E6T) was derived
from B2BE6 cells that had been passaged once in nude mice and
recultured in vitro. These cells were shown to be derived from
BEAS-2B by karyotypic analysis (Noguchi et al, 1993).
Construction of the TGF-a mRNA retroviral expression
vector
Sense and antisense expression vectors for TGF-a were prepared
by subcloning a 924-bp restriction fragment that contains the
complete coding sequence for TGF-ax (Jhappan et al, 1990) into
the XhoI site of the pLTRneo vector (DiFiore et al, 1987). The
neomycin resistance gene of pLTRneo was replaced by a Sall
hygromycin resistance cassette. This cassette was generated in
pSV2hygro (Southern and Berg, 1982), which contains a unique
Sall site 5' of the hygromycin resistance gene. An XmnI-HpaI
fragment from pSV2neo was inserted in place of the XmnI-HpaI
fragment of pSV2hygro. This manoeuvre inserted a second Sall
site 3' of the hygromycin resistance gene, generating the Sall
hygromycin cassette, which could be exchanged for the Sall
neomycin cassette, originating from pSV2neo, contained in
pLTRneo (DiFiore, 1987).
Transfection and subcloning
To obtain TGF-c-producing E2 cells, cells were transfected with
the TGF-x sense vector by DNA strontium phosphate co-precipi-
tation as previously described (Noguchi et al, 1993). Mass cultures
of hygromycin-resistant cells were frozen. They were later cloned
by limiting dilution in 96-well plates and expanded into cell lines.
The TGF-a antisense expression vector was introduced into E6T
clones using Lipofectin (Gibco-BRL, Gaithersburg, MD, USA)
according to the manufacturer's protocol. Cells (1 x 106) were
plated into 100-mm dishes and transfected with 10,g of TGF-ax
cDNA cloned in the antisense direction. The cells were exposed to
the Lipofectin-DNA mixture for 4 h. Two days after transfection,
the vector containing cells were grown in LHC-8 media containing
3% chemically denatured serum (UBI, Lake Saranac, NY, USA)
and hygromycin (200,g ml') (Sigma, St Louis, MO, USA). The
cell culture medium was changed twice weekly. Transformed cells
were cloned using cylinders 22 days after transfection and
expanded into cell lines.
Tumorigenicity assay
Athymic nude mice were irradiated 24 h before inoculation with
3.5 Gy using a 60Co irradiation source. Mice were inoculated
subcutaneously in a single site with each of the cell lines tested
(5 x 106 cells per mouse) and were monitored weekly for tumour
formation for 52 weeks or until sacrifice.
TGF-a detection
Media conditioned for 48 h by 70% confluent cell cultures in T75
flasks (2 x 106 cells per flask) were concentrated tenfold using
Centricon-3 filters (Amicon, Danvers, MA, USA). When media
were collected, cells were trypsinized and counted, using a haema-
cytometer to determine the final cell number. The media were
frozen at -20°C until the time of assay. The enzyme-linked
immunosorbent assay (ELISA) was performed using a commer-
cially available kit (Oncogene Science, Mineola, NY, USA) with
a sensitivity of 50 pg ml'. TGF-x concentration was calculated
as pg ml' per million cells. Two independent experiments were
performed. In each experiment, medium was collected from two
separate cultures per cell line and ELISA values were measured in
duplicate for each culture. The presence of membrane-associated
TGF-a was determined by indirect immunofluorescence and
FACS analysis. Cells were harvested using trypsin EDTA. Cells
were incubated for 3 min at 4°C with 0.2 M acetic acid, 0.5 M
sodium chloride pH 2.5 to remove secreted TGF-a bound to cell-
surface receptors. Unfixed cells were labelled at 4°C for 1 h with a
monoclonal antibody against human TGF-a (Ab-2, Oncogene Sci)
and a fluorescein-labelled rabbit anti-mouse antibody (Sigma).
Immunoblot analysis
Cells were grown to 90% confluence in 100-mm2 tissue culture
dishes in LHC-8 media. The cells were starved for 4 h in LHC-8
basal medium without epidermal growth factor (EGF), (UBI, Lake
Saranac, NY, USA) but supplemented with insulin (5 jg ml-'),
transferrin (5 jig ml-') and selenium (5 ng ml-') (Sigma). Sodium
orthovanadate (100 jM) was added in the last hour of incubation.
For stimulated samples, 15 min before lysis, cells were treated at
37°C with EGF (50 ng ml') or TGF-a (20 ng ml-') (Gibco-BRL).
British Journal ofCancer (1998) 77(7), 1066-1071 . CancerResearch Campaign 19981068 AWHamburger etal
Cells were then washed three times with cold phosphate-buffered
saline (PBS), lysed in RIPA (50 mm Tris, pH 7.4, 150 mm sodium
chloride, 1% Triton X-100, 1% deoxycholic acid, sodium salt,
0.1% sodium dodecyl sulphate (SDS), 100 jg ml phenylmethyl-
suphonyl fluoride (PMSF), 1 jig ml- aprotinin, 1 mm dithiothre-
itol (DTT), 1 mm sodium orthovanadate) buffer for 10 min and
scraped. The extracts were centrifuged at 16 000 g for 30 min at
4°C. For analyses of EGFR and ErbB-2, lysates (100 jg per
sample) were resolved on 7.5% SDS gels. For immunoprecipita-
tion, approximately 1 mg of lysate was incubated overnight with
1 jg of antibody to EGFR (antibody 528, Oncogene Science,
Mineola, NY, USA) and 15 ,ul of protein A-protein G Agarose
(Oncogene Science). Immunoprecipitates were centrifuged at
7500g for 20 min and then washed four times for 5 min each with
PBS and 0.05% Tween-20. Beads were resuspended in 2 x sample
buffer and heated at 95°C for 5 min. Supernatants were elec-
trophoresed on 7.5% polyacrylamide gels and electrophoretically
transferred to Immobilon-P membranes (Millipore, Bedford, MA,
USA). Blots were stained with a 1:500 dilution of antibody to
ErbB-2 (antibody 3 Oncogene Science), or a 1:500 dilution ofanti-
body to EGFR (SC-03, Santa Cruz Laboratories, Santa Cruz, CA,
USA). One to ten-thousandfold dilutions ofappropriate secondary
antibodies (Amersham, Arlington Heights, IL, USA) were used for
detection. Blots were visualized using an enhanced chemilumines-
cence (ECL) kit and Hyperfilm (Amersham).
RESULTS
Manipulation of TGF-a production in clonal isolates
To evaluate the contribution of TGF-a production to tumori-
genicity, cultures of non-tumorigenic E2 cells were transfected
with the TGF-a sense expression vector (for construction, see
Materials and methods), cloned by limiting dilution and expanded
into cell lines (E2ax cells). In addition, tumorigenic E6T cells were
transfected with a TGF-a antisense vector and subcloned to
produce the E6TA cell line. TGF-a protein levels in conditioned
media were measured using a TGF-a-specific ELISA. Twelve
TGF-ca-sense transfected clones were isolated. Cells secreted
between 22 and 62 pg TGF-a per ml per 106 cells in 48 h. The
TGF-a production of the five clones inoculated into nude mice is
presented in Table 1. E6T cells, the tumorigenic line derived after
passage in nude mice, produced 243 pg of TGF-a per ml per 106
cells. Four clones of E6TA cells were also isolated. All clones
secreted approximately 5% of the level ofTGF-a as produced by
E6T. The E6TA clone injected into nude mice showed a 94%
reduction in TGF-a protein levels to 17 pg per ml per 106 cells.
Wethen evaluated membrane-bound TGF-a fromE6T, E2, E6TA
and E2a 2B3 cells by indirect immunofluorescence and FACS
analyses. Of 15 000 cells examined, no E2 or E6TA cells stained
positive for TGF-a. In contrast, 8.1 % and 18.9% ofE2a and E6T
cells, respectively, wereTGF-apositive. Mean fluorescence percell
was approximately 5% greater for E6T than E2a cells.
Tumorigenicity assay
A representative sample ofthe transfected cell lines was tested for
tumorigenic potential by s.c. inoculation in athymic nude mice.
Table 1 compares TGF-ax production and tumorigenicity. E6T cells
expressed a relatively high tumorigenic potential with small
(60 mm3) tumours first observed after a mean latency of 9 weeks
Table 1 Tumorigenicity of ErbB-2 transfected BEAS 2B cells in athymic
nude mice
Number of tumours
Cell line TGF-a (pg per 106 cells) number of micea
E2 0.2 ± 0.2b 0/20
E6T 243 ±8 7/10
E6TA 17±1 0/10
E2a transfectants
E2a 1D4 36 ± 4 0/10
E2a 3A3 38 ± 6 0/10
E2a 1C5 27± 1 0/10
E2a 2B3 62 ± 7 0/10
E2a 1C3 22± 1 0/10
aThe number of tumours observed; bmean ± s.d. (four wells).
in seven out of ten animals. All tumours continued to grow,
reaching more than 2000 mm3 by 22 weeks. All tumours were
examined morphologically and classified as adenocarcinomas
with polygonal neoplastic cells lining cystic spaces. Cells from
one experimental tumour were explanted and examined. Cells
were of human origin as determined by karyotypic analysis. Cells
placed back into in vitro culture continued to secrete TGF-a (300
pg ml-' per 106 cells) into conditioned media. In contrast, no
tumours were observed after 52 weeks in mice inoculated with 5
E2ax cell lines or with the E6TA cells. The differences in tumours
incidence of E6T cells and the E6TA, E2, or E2a clones were
statistically significant at P < 0.05 using Fisher's exact test.
EGFR and ErbB-2 status
As the biological consequences of interactions of EGFR ligands
with cells is dependent on the status of EGFR and ErbB-2, we
examined levels of EGFR and ErbB-2 in clones that had been
injected into nude mice. The data in Figure 1 indicate that roughly
equivalent levels ofEGFR were expressed in the non-tumorigenic,
non-TGF-a-producing E2 and the tumorigenic E6T cells. EGFR
was expressed at higher levels in the non-tumorigenic E2ax clone
(2B3) and the TGF-a antisense clone E6TA.
The levels of ErbB-2 were also examined by Western blot
analysis (Figure 2) and were equivalent in the tumorigenic E6T,
and non-tumorigenic E6TA and E2 cells. In contrast, the E2a cells
(clone 2B3) greatly overexpressed erbB-2.
Heterodimerization of EGFR with ErbB-2
We previously postulated that chronic stimulation of EGFR by
autocrine production ofTGF-ax in E6T cells led to heterodimeriza-
tion of EGFR with ErbB-2 (Noguchi et al, 1993). To evaluate
EGFRIErbB-2 heterodimer formation, E2, E2a (clone 2B3), E6T
and E6TA cells were starved and treated with EGF or TGF-ax
as described and then lysed and immunoprecipitated with antibody
to EGFR. Immunoprecipitates were electrophoresed and immuno-
blotted with antibody to ErbB-2. As shown in Figure 3A, ErbB-2
was detected in immunoprecipitates ofEGFR in unstimulated E6T
and E2a cells, but not unstimulated E2 and E6TA cells suggesting
a requirement for TGF-a (Figure 3B). Incubation with exogenous
TGF-a induced detectable association ofErbB-2 with EGFR in E2
and E6TA cells as expected (King et al, 1988).
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Figure 1 Expression of EGFR in ErbB-2 overexpressing cells. Lysates of the
indicated cell lines were resolved in SDS-polyacrylamide gels, blotted onto
PVDF membranes and probed with an antibody to EGFR (A) or actin (B)
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A
ErbB-2-+
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Figure 2 Expression of ErbB-2. Lysates of the indicated cells lines were
resolved in SDS-polyacrylamide gels, blotted onto PVDF membranes, and
probed with antibodies to ErbB-2 (A) or actin (B)
DISCUSSION
Overexpression of normal erbB-2 has been linked to shortened
survival in lung adenocarcinoma (Kern et al, 1994), suggesting
that the expression of this proto-oncogene may contribute to
tumour progression. However, several studies (Pierce et al, 1991;
Ciardello et al, 1992) indicate that additional genetic changes are
necessary to elicit a fully tumorigenic phenotype in erbB-2 trans-
fected human epithelial cells.
In an attempt to further understand this problem in the context
of human lung adenocarcinoma, we examined the consequences
of the overproduction of ErbB-2 in the T-antigen-expressing
immortalized human bronchial epithelial cell line, BEAS-2B. We
(Noguchi et al, 1993) hadpreviously demonstrated that the tumori-
genicity ofclones oferbB-2 transfected cells did not correlate with
the level of expression of ErbB-2. However, we observed that
tumorigenic clones produced the EGFR ligand TGF-ac. We postu-
lated that interactions between TGF-a and EGFR could be impor-
tant in inducing a malignant phenotype by heterodimerization and
subsequent activation ofErbB-2.
To this end, we transfected tumorigenic TGF-a-producing cells
(E6T) with an antisense vector that inhibited TGF-a production
as demonstrated by immunoassays for the protein. Such cells
were unable to produce tumours in nude mice. Conversely, non-
tumorigenic, non-TGF-a-producing cells were transfected with an
expression vector for TGF-ax. Cells isolated after this transfection
increased TGF-a production approximately 30-fold. However,
this amount of TGF-a production was only 25% of that observed
for the tumorigenic clone and these cells were non-tumorigenic
erbB2
Figure 3 Co-immunoprecipitation of ErbB-2 with EGFR. Cells were
untreated (0) or were treated with EGF (50 ng ml-') or TGF-a (20 ng ml-') as
described. Cells were lysed and the cleared supematants were
immunoprecipitated with antibody against EGFR, subjected to SDS-PAGE,
transferred to PVDF filters and probed with antibody to erbB-2. (A) E6T cells
(lanes 1 and 2) and an E2a transfectant (2B3) (lanes 3-5) (B) E2 cells, E6TA
(E6 cells, transfected with the TGF-a antisense plasmid)
(Table 1). These results suggest that a critical level of TGF-a is
needed to induce tumour formation in vivo. As cell-surface-
associated TGF-ax has been shown to influence cell growth in a
juxtracrine manner (Massague, 1990), cell lines were evaluated by
FACS analysis after staining with anti TGF-a antibody. No cell-
surface TGF-a was detected on E2 or E6TA cells. In contrast, the
mean level of fluorescence and the numbers ofpositive cells were
greater for E6T than E2a 2B3 consistent with the levels ofTGF-a
secreted by these cells (Table 1).
The requirement forhigh levels ofsecreted TGF-ax in this ErbB-
2 overexpression system suggests that a threshold level of active
heterodimers is necessary for tumorigenic conversion. Therefore,
we evaluated the constitutive expression levels of EGFR and
ErbB-2 in the four classes ofclones. No obvious correlation could
be made between the degree ofEGFR overexpression and tumori-
genicity. The ratio of EGFR to ErbB-2 was roughly similar in
tumorigenic E6T cells and non-tumorigenic E2 cells. High EGFR
expression was noted in both clones of transfected cells. Whether
the presence of high EGFR levels was due to the transfection
procedure or random clonal variation is not known.
ErbB-2 levels were roughly equivalent in all clones, except the
E2a clone 2B3. This line produced a very high level of ErbB-2
receptor. These data agree with our previous finding that the
degree ofoverexpression ofErbB-2 did not correlate with tumori-
genicity (Noguchi et al, 1993). The high degree ofErbB-2 expres-
sion in 2B3 may be typical of the E2 TGF-a transfected cells, or
may be due to random clonal variation.
In the present study, we have demonstrated constitutive
EGFR/ErbB-2 complexes in the TGF-a producing E6T and E2ax
clones. However, complexes were demonstrated in all cells tested
in the presence of exogenous EGF and TGF-a, indicating that
EGFR and ErbB-2 were capable of heterodimerizing in the pres-
ence of ligand. We hypothesized that the secretion of TGF-at in
E6T cells induced constitutive heterodimer formation between
EGFR and ErbB-2 and a change in configuration of ErbB-2.
Stimulation ofmitogenic pathways by this activated complex may
have contributed to the development of a tumorigenic phenotype
in E6T cells. Although in vitro heterodimerization ofEGFR-ErbB-
2 was observed in E2ax cells, tumour formation was absent. The
presence of EGFR-ErbB-2 heterodimers may not strictly correlate
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with the tumorigenic phenotype as recently demonstrated by
Muller et al (1996) in transgenic mice bearing mammary tumours.
In addition, neither the number ofEGFR-ErbB-2 heterodimers nor
their distribution was analysed in our study. These factors may
also have contributed to the differential expression of the tumori-
genic phenotype.
In this study, we did not examine downstream molecules in the
EGFR-ErbB-2 signal transduction pathway. However, immuno-
blot analysis revealed that both EGFR and ErbB-2 were constitu-
tively tyrosine phosphorylated in E2 and E6T cells. Constitutive
tyrosine phosphorylation in the absence of ligand stimulation has
been similarly noted in human breast cancer cell lines (Alimandi et
al, 1995) and is thought to be due to overexpression of ErbB-2.
These data are consistent with the possibility that different tyro-
sine residues may be phosphorylated and quantitatively different
distributions of heterodimers and docking of downstream
signalling molecules may occur in the different cell lines.
A very complex series of ligand-receptor interactions regu-
lating the biological function ofErbB family receptors is emerging
(Riese et al, 1995; Chen et al, 1996; Karunagaran et al, 1996). It is
becoming clear that there exist ligand-dependent hierarchies of
heterodimer formation among ErbB receptors in response to
specific ligands that continue to be discovered (Carraway et al,
1997; Chang et al, 1997). Ligands specific for one receptor may
activate other receptors to which they do not directly bind. We
have demonstrated that all cell variants described in this report
also express ErbB-3 and ErbB-4 (A Fernandes, in preparation). It
is known that stimulation of EGFR by EGFR-specific ligands,
such as amphiregulin, TGF-a and EGF, can activate both ErbB-3
(Kim et al, 1994) and Erb-4 (Tzahr et al, 1996). Thus, forexample,
it is possible that activation of ErbB-3 occurs only in tumorigenic
cells with subsequent increased enzymatic activity of downstream
signalling molecules, such as phosphatidylinositol 3-kinase, that
are selectively and potently recruited by ErbB-3. Future work will
evaluate these receptor interactions.
In summary, we have demonstrated that a high level of expres-
sion ofTGF-ax in ErbB-2-overexpressing human bronchial epithe-
lial cell lines was necessary for the induction of the tumorigenic
phenotype. The clonal cell lines E2 and E6T and their TGF-x
derivatives should provide a model system for the study of
heterodimeric signalling by ErbB family members in lung epithe-
lium and the consequences of these signals for tumorigenic
progression.
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